NuCana (FRA:N040) Notes Receivable: €0.00 Mil (As of Mar. 2026)


FRA:N040 NuCana PLC FRA:N040
25 GF Score
Price €3.20
! 2 Warning Signs
View Full Analysis

What is NuCana Notes Receivable?

NuCana FRA:N040 25 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:N040 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review.

NuCana's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

NuCana Notes Receivable Historical Data

* Premium members only.

The historical data trend for NuCana's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NuCana Notes Receivable Chart

NuCana Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NuCana Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:N040
25GF Score
NuCana PLC FRA:N040
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NuCana Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
NuCana (FRA:N040) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on NuCana and its competitors.
Is NuCana's Notes Receivable too high?
NuCana's current Notes Receivable is €0.00 Mil. Overall, NuCana has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does NuCana's Notes Receivable compare to LABT and APM?
NuCana's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on NuCana and its competitors. NuCana's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NuCana stock overvalued right now?
NuCana (FRA:N040) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. NuCana's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For NuCana (FRA:N040), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NuCana Business Description

Other Exchanges NCNA:USA
Address 3 Lochside Way, Edinburgh, GBR, EH12 9DT
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
25GF Score

Get the complete analysis for FRA:N040

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.20
Price